Skip to Main Content

Close

ASH
ASH Clinical News
ASH Image Bank Open External Link
ASH News Daily
ASH-SAP
Blood Journals
Hematology
The Hematologist
International

header search

search input Search input auto suggest

filter your search

Search

Menu

Issues
- Current issue
- All Issues
CMEOpen External Link
About

Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 2019, Issue 1

December 6 2019

Hematology Cover Image for Volume 2019, Issue 1

In this Issue

Ham-Wasserman Lecture
Acute Lymphoblastic Leukemia: Aiming High to Keep MRD Low, or Even Better, Negative
Aggressive Non-Hodgkin Lymphomas: It’s Getting Personal
Aging and Hematologic Disorders: Exploring the Evidence
Balancing the Scales: Management of Patients at Risk of Bleeding and Clotting in the Acute Care Setting
Bone Marrow Failure and Clonal Evolution
Challenges in Myeloma Therapy
Coagulation Conundrum Roundtable: Case-Based Discussion on the Implications of Exogenous Estrogens in Hemostasis and Thrombosis
Combined Basic Science and Education Session on Cancer-Associated Thrombosis
DOACs in the Real World
Expanding Horizons for Immunotherapy in Pediatric Leukemia
Hodgkin Lymphoma: Celebrating 200 Years since Thomas Hodgkin Entered Medicine
Immunotherapy in Myeloma
Indolent Lymphomas: The Marathon Has a New Course
Inflammation and Hematopoiesis: The Impact of Inflammation on the Bone Marrow Microenvironment
Iron: How to Manage When There Is Too Much or Too Little of It
Management of Sickle Cell Disease Complications Beyond Acute Chest
Myelodysplastic Syndromes: From Mild-Mannered to Lurking Leukemia
Myeloproliferative Neoplasms: Managing the Cup That Runneth Over
New Diagnostic and Treatment Strategies for Antiphospholipid Syndrome
Patients, Borders, Money, and Mission: A Global Perspective of Chronic Myeloid Leukemia
Primary Immunodeficiencies: Finding the Needle in the Haystack
Response Comes of Age in Chronic Lymphocytic Leukemia
Sickle Cell Disease in Young and Old: A Time for Re-Evaluation
Spoiled for Choice: Donor Selection for Allogeneic Stem Cell Transplantation
Therapy of Acute Myeloid Leukemia: Adapting to Change
Transfusion Medicine: Optimizing Patient Blood Management (PBM)
What's New in the Diagnosis and Management of von Willebrand Disease?
Why Patients Fail after Allogeneic Stem Cell Transplantation
Erratum

Table of Contents

Ham-Wasserman Lecture

Gene therapy for hemophilia

Amit C. Nathwani

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Acute Lymphoblastic Leukemia: Aiming High to Keep MRD Low, or Even Better, Negative

Navigating the nexus of MRD and novel agents in ALL

Anjali S. Advani,Edward A. Copelan

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit?

Lori Muffly,Emily Curran

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Curing Ph⁺ ALL: assessing the relative contributions of chemotherapy, TKIs, and allogeneic stem cell transplant

Adele K. Fielding

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Aggressive Non-Hodgkin Lymphomas: It’s Getting Personal

Molecular profiling and management of mantle cell lymphoma

Jia Ruan

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Emerging strategies in peripheral T-cell lymphoma

Neha Mehta-Shah

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Prognostication with circulating tumor DNA: is it ready for prime time?

David M. Kurtz

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Aging and Hematologic Disorders: Exploring the Evidence

Ready for prime time: role for geriatric assessment to improve quality of care in hematology practice

Heidi D. Klepin

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Evidence-Based Minireview: Longitudinal geriatric assessment in quality care for older patients with hematologic malignancies

Richard J. Lin,Heidi D. Klepin

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Delivering intensive therapies to older adults with hematologic malignancies: strategies to personalize care

Rebecca L. Olin

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Balancing the Scales: Management of Patients at Risk of Bleeding and Clotting in the Acute Care Setting

Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy

Hanny Al-Samkari,Jean M. Connors

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Management of rare acquired bleeding disorders

Marzia Menegatti,Eugenia Biguzzi,Flora Peyvandi

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Bleeding in critical care associated with left ventricular assist devices: pathophysiology, symptoms, and management

F. W. G. Leebeek,R. Muslem

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Bone Marrow Failure and Clonal Evolution

Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome

Jibran Durrani,Jaroslaw P. Maciejewski

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Monitoring and treatment of MDS in genetically susceptible persons

Stella M. Davies

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Genetic predisposition to MDS: diagnosis and management

Elissa Furutani,Akiko Shimamura

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Challenges in Myeloma Therapy

Roundtable: How I treat a newly diagnosed patient with high-risk myeloma

Jonathan L. Kaufman

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

How I treat a refractory myeloma patient who is not eligible for a clinical trial

Siyang Leng,Divaya Bhutani,Suzanne Lentzsch

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

What to do with minimal residual disease testing in myeloma

Elisabet E. Manasanch

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Surbhi Sidana,Elisabet Manasanch

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Coagulation Conundrum Roundtable: Case-Based Discussion on the Implications of Exogenous Estrogens in Hemostasis and Thrombosis

Case-based discussion on the implications of exogenous estrogens in hemostasis and thrombosis: the obstetrician’s view

Andra H. James

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Case-based discussion on the implications of exogenous estrogens in hemostasis and thrombosis: the hematologist’s view

Margaret V. Ragni

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Combined Basic Science and Education Session on Cancer-Associated Thrombosis

What's new in the prevention and treatment of cancer-associated thrombosis?

Miriam Kimpton,Marc Carrier

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Update from the clinic: what’s new in the diagnosis of cancer-associated thrombosis?

Erica A. Peterson,Agnes Y. Y. Lee

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin

Katsue Suzuki-Inoue

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Update from the laboratory: mechanistic studies of pathways of cancer-associated venous thrombosis using mouse models

Yohei Hisada,Nigel Mackman

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

DOACs in the Real World

Is there a role for low-dose DOACs as prophylaxis?

Alexander T. Cohen,Beverley J. Hunt

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Direct oral anticoagulant monitoring: what laboratory tests are available to guide us?

Ravi Sarode

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

What we have learned about direct oral anticoagulant reversal

Deborah M. Siegal

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor–associated major bleeding

Miriam Kimpton,Deborah M. Siegal

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Expanding Horizons for Immunotherapy in Pediatric Leukemia

Moving immunotherapy into the front line in ALL

Amanda Winters,Lia Gore

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Opportunities for immunotherapy in childhood acute myeloid leukemia

Adam J. Lamble,Sarah K. Tasian

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Mechanisms of and approaches to overcoming resistance to immunotherapy

Liora Schultz,Rebecca Gardner

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Hodgkin Lymphoma: Celebrating 200 Years since Thomas Hodgkin Entered Medicine

Management of older Hodgkin lymphoma patients

Andrew M. Evens,Jordan Carter,Kah Poh Loh,Kevin A. David

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Novel agents and immune invasion in Hodgkin lymphoma

Reid W. Merryman,Ann LaCasce

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Evidence-Based Minireview: What is the optimal timing of anti–PD-1 antibodies in relapsed classical Hodgkin lymphoma?

Pamela Blair Allen,Ann S. LaCasce

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment

Scott F. Huntington

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Immunotherapy in Myeloma

CAR T-cell therapy: is it prime time in myeloma?

Surbhi Sidana,Nina Shah

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Myeloma: next generation immunotherapy

Adam D. Cohen

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Indolent Lymphomas: The Marathon Has a New Course

Targeting CD20: teaching an old dog new tricks

Jeff P. Sharman

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Indolent lymphomas: pushing the pace with novel agents

Caron A. Jacobson

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Where does transplant fit in the age of targeted therapies?

Victor A. Chow,Ajay K. Gopal

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Inflammation and Hematopoiesis: The Impact of Inflammation on the Bone Marrow Microenvironment

Inflammatory bone marrow microenvironment

Nils B. Leimkühler,Rebekka K. Schneider

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Microbiota modification in hematology: still at the bench or ready for the bedside?

Christopher J. Severyn,Ryan Brewster,Tessa M. Andermann

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Iron: How to Manage When There Is Too Much or Too Little of It

Management of iron deficiency

Shuoyan Ning,Michelle P. Zeller

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Evidence-Based Minireview: The role of IV iron in management of patients with iron-deficiency anemia presenting to the emergency department

Julia G. Ramos,Michelle P. Zeller

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

New diagnostic tools for delineating iron status

Yelena Z. Ginzburg

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Iron overload in transfusion-dependent patients

Thomas D. Coates

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Management of Sickle Cell Disease Complications Beyond Acute Chest

Management of liver complications in sickle cell disease

Abid R. Suddle

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Osteonecrosis in sickle cell disease: an update on risk factors, diagnosis, and management

Oyebimpe O. Adesina,Lynne D. Neumayr

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Complications in pregnant women with sickle cell disease

Kim Smith-Whitley

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Myelodysplastic Syndromes: From Mild-Mannered to Lurking Leukemia

Lowering the boom on lower-risk myelodysplastic syndromes

Mikkael A. Sekeres,Bhumika J. Patel

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Integrating patient-centered factors in the risk assessment of MDS

Rena J. Buckstein

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

In MDS, is higher risk higher reward?

Guillermo F. Sanz

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Myeloproliferative Neoplasms: Managing the Cup That Runneth Over

Diagnostic workflow for hereditary erythrocytosis and thrombocytosis

Mary Frances McMullin

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms

Brady L. Stein,Karlyn Martin

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN

Aaron T. Gerds

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

New Diagnostic and Treatment Strategies for Antiphospholipid Syndrome

Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome

Michelle Petri

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

What’s new in obstetric antiphospholipid syndrome

D. Ware Branch

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Is there a role for immunosuppression in antiphospholipid syndrome?

Ecem Sevim,Rohan Willis,Doruk Erkan

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Patients, Borders, Money, and Mission: A Global Perspective of Chronic Myeloid Leukemia

Meeting the needs of CML patients in resource-poor countries

Hemant Malhotra,Jerald Radich,Pat Garcia-Gonzalez

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Primary Immunodeficiencies: Finding the Needle in the Haystack

Primary immunodeficiencies: novel genes and unusual presentations

Luigi D. Notarangelo,Gulbu Uzel,V. Koneti Rao

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Common variable immune deficiency: case studies

Charlotte Cunningham-Rundles

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Treatment of primary immunodeficiency with allogeneic transplant and gene therapy

Sung-Yun Pai

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Response Comes of Age in Chronic Lymphocytic Leukemia

Clonal dynamics in chronic lymphocytic leukemia

Catherine Gutierrez,Catherine J. Wu

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Jennifer A. Woyach

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Relapsed disease and aspects of undetectable MRD and treatment discontinuation

Barbara Eichhorst,Moritz Fürstenau,Michael Hallek

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Sickle Cell Disease in Young and Old: A Time for Re-Evaluation

Sickle cell disease: a comprehensive program of care from birth

Mariane de Montalembert,Léon Tshilolo,Slimane Allali

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

A program of transition to adult care for sickle cell disease

Anjelica C. Saulsberry,Jerlym S. Porter,Jane S. Hankins

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Optimal disease management and health monitoring in adults with sickle cell disease

Jo Howard,Swee Lay Thein

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Spoiled for Choice: Donor Selection for Allogeneic Stem Cell Transplantation

How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide

Shannon R. McCurdy,Leo Luznik

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Optimizing cord blood selection

Annalisa Ruggeri

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Selection of matched unrelated donors moving forward: from HLA allele counting to functional matching

Katharina Fleischhauer

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Therapy of Acute Myeloid Leukemia: Adapting to Change

The growing landscape of FLT3 inhibition in AML

Catherine C. Smith

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Single-agent and combination biologics in acute myeloid leukemia

Guillaume Richard-Carpentier,Courtney D. DiNardo

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

MRD evaluation of AML in clinical practice: are we there yet?

Sylvie D. Freeman,Christopher S. Hourigan

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Transfusion Medicine: Optimizing Patient Blood Management (PBM)

Preoperative anemia-screening clinics

Yulia Lin

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Clinical decision support and improved blood use in patient blood management

Lawrence Tim Goodnough,Marie A. Hollenhorst

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Patient blood management as the standard of care

Michael F. Murphy,Antony Palmer

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

What's New in the Diagnosis and Management of von Willebrand Disease?

New therapies for von Willebrand disease

Pier Mannuccio Mannucci

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

New advances in the diagnosis of von Willebrand disease

Ruchika Sharma,Sandra L. Haberichter

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Evidence-Based Minireview: Perioperative management of the VWD patient at elevated thrombotic risk

Holleh D. Husseinzadeh,Sandra Haberichter

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Perioperative management of patients with von Willebrand disease

James S. O’Donnell,Michelle Lavin

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Why Patients Fail after Allogeneic Stem Cell Transplantation

Clonal evolution and immune evasion in posttransplantation relapses

Luca Vago

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Minimal residual disease and stem cell transplantation outcomes

Jacqueline Cloos,Gert J. Ossenkoppele,Richard Dillon

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Cause-specific late mortality after allogeneic stem cell transplantation

Smita Bhatia

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Erratum

Scherber RM, Mesa RA. Managing myelofibrosis (MF) that “blasts” through: advancements in the treatment of relapsed/refractory and blast-phase MF. Hematology Am Soc Hematol Educ Program. 2018;2018:118-126.

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Cover Image

Cover Image

T cells and brain cancer cell. The image is a composite colored scanning electron micrograph of T cells and an apoptotic brain cancer cell. T cells are a component of the body’s immune system. Chimeric antigen receptor (CAR) T-cell therapy takes T cells from a cancer patient’s blood and modifies them to recognize a specific protein found on the patient’s tumor cells. When reintroduced into the patient, the T cells find and destroy the tumor cells. The newest form of CAR T-cell therapy, now in clinical trials, uses “memory” T cells, which remain in the body after attacking the cancer. The hope is that memory T cells may provide an active reservoir of cancer-killing cells capable of stopping further tumors. Magnification ×6000 at 10 cm wide. Source: Steve Gschmeissner/Science Photo Library.
Front Matter
Table of Contents

Latest
Most Read
Most Cited

Targeted medical therapies for vascular anomalies

T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma

Transplant in ALL: who, when, and how?

Ph− ALL: immunotherapy in upfront treatment

Ph+ ALL: new approaches for upfront therapy

American Society of Hematology
2021 L Street NW, Suite 900
Washington, DC 20036
TEL +1 202-776-0544
FAX +1 202-776-0545

ASH Publications

Blood
Blood Advances
Blood Global Hematology
Blood Immunology & Cellular Therapy
Blood Neoplasia
Blood Red Cells & Iron
Blood Vessels, Thrombosis & Hemostasis
Hematology, ASH Education Program
ASH Clinical News
ASH-SAP
The Hematologist

American Society of Hematology

ASH Home
ASH Image Bank
ASH Store

Advocacy
Education
Meetings
Research

Copyright 2025 by American Society of Hematology

Cookie Settings
Privacy Policy
Cookie Policy
Terms of Use
Contact Us

This Feature Is Available To Subscribers Only

Sign In or Create an Account